What Hospitalists Need to Know About Sickle Cell Disease

Additional information
Bibliography: 
  • Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., ... & Wang, S. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), 1139-1151.
  • Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., ... & Becker, R. C. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), 883-891.
  • Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., ... & Bahit, M. C. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. 
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Speaker Credit™
Course opens: 
05/01/2018
Course expires: 
05/01/2020
Rating: 
0

Available Credit

  • 2.00 AMA PRA Category 1 Speaker Credit™

Accreditation Period

Course opens: 
05/01/2018
Course expires: 
05/01/2020
Please login or register to take this course.